Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.34 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 6/20 | 0.32 |
| ▸ | PPARA | Q07869 | 6/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5020347 | 0.94 | TGFBR1 (0.36) | HSP90AA1TGFBR1HKDC1DUSP3PTPN11 | |
| SCHEMBL5020366 | 0.89 | CCR1 (0.41) | HSP90AA1HKDC1DUSP3PTPN11P2RX7 | |
| SCHEMBL5020365 | 0.89 | CCR1 (0.35) | HSP90AA1HKDC1DUSP3PTPN11P2RX7 | |
| SCHEMBL5020377 | 0.89 | HSP90AA1 (0.34) | HSP90AA1HKDC1DUSP3PTPN11P2RX7 | |
| SCHEMBL5020444 | 0.89 | NPC1 (0.36) | HSP90AA1HKDC1DUSP3PTPN11P2RX7 | |
| SCHEMBL5020348 | 0.88 | TGFBR1 (0.34) | TGFBR1PPARGPPARAFFAR1 | |
| SCHEMBL5020219 | 0.86 | CCR1 (0.34) | HSP90AA1HKDC1P2RX7CCR1CCR8 | |
| SCHEMBL5020229 | 0.85 | TGFBR1 (0.34) | TGFBR1FFAR1CCR1CCR8 | |
| SCHEMBL10289685 | 0.85 | CCR1 (0.33) | HSP90AA1CCR1CCR8 | |
| SCHEMBL5020302 | 0.85 | KCNH2 (0.36) | HSP90AA1KCNH2CCR1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045873-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045873-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| WO-2012062844-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045873-A1 | NOVEL MICROBIOCIDES | MSR1, CD209, C3AR1 | HSP90AA1 1228/4885TGFBR1 1875/4885HKDC1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.